Skip to main content
OpenTrials
Completed

NCT Number: NCT04663360

Medication Monitoring for Older Adults in Primary Care

Polypharmacy has the potential to harm older adults by causing cognitive impairment, falls, and hospitalisations. Many adverse drug reactions could be prevented with closer monitoring. This project will establish the effectiveness of the nurse-led intervention - the ADRe Profile - for medicines commonly prescribed in primary care and evaluate intervention implementation in general practices.

Completed

Looking for future studies?

Notify Me

Key information

Age range

64 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aneurin Bevan Health Board

Newport, Gwent, NP18 3XQ, United Kingdom

About this study

The number of medicines people take is increasing. Older adults are particularly at risk of adverse drug reactions due to polypharmacy. Adverse drug reactions cause avoidable patient harm, and around 5-8% of unplanned hospital admissions in the UK, costing the NHS £1.5-2.5bn pa. Many adverse drug reactions could be prevented with closer monitoring. The nurse-led Adverse Drug Reactions Profile (ADRe Profile) represents a unique instrument that records patients' observations and self-reported information on signs and symptoms that is likely to relate to an adverse reaction to medications. This project will establish the effectiveness of ADRe Profile in identifying patient problems possibly resulting from medicines in general practices and will be implemented in 3 phases.

Phase 1 (4 months) Validity and reliability testing of the ADRe Profile will be performed with key stakeholders (patients, nurses, care assistants, GP's and pharmacists), before introducing the tool to general practices. Feasibility testing will also be undertaken.

Phase 2 (12 months) The aim of this phase is to test whether the ADRe Profile identifies and ameliorates health problems. The practice nurse (or the researcher) will perform an ADRe consultation with a group of eligible service users and compare the number and nature of health and well-being problems identified with a similar group of service users who receive normal care.

Phase 3 (6 months) Finally, to further explore the impact of the ADRe Profile, the researchers will conduct semi-structured interviews with health professionals (nurses, care assistants, GPs and pharmacists) and service users.

The investigators hope that this study will help patients gain maximum benefits from their medicines and support nurses, pharmacists and GP's to reduce any bothersome side effects and problems that, if not addressed promptly, can lead to hospital admissions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

Patients:

  • age > 64 years
  • with a long-term condition
  • prescribed > 5 medications daily. (Vitamin and nutritional supplements and moisturising skin preparations will not be counted as 'medicines'.)
  • Willing and able to give informed, signed consent themselves, or where capacity is lacking in the opinion of their nurses, a consultee/representative accompanying the patient who is willing to give advice and assent to the service user participating and sign on their behalf.

Exclusion criteria

Patients:

  • Age < 64 years
  • Without any long-term conditions
  • Prescribed < 5 medications daily
  • Not willing to participate
  • Unable to consent and no consultee/representative present
  • Not fluent in English or Welsh (unless a family member can assist with translation)
  • Receiving palliative care
  • Expected to remain in the practice for the next 12 months

Treatment and study plan

Adverse Drug Reaction (ADRe) Profile

Other

ADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts.

Primary outcomes

  1. Level of completion of all items in the video call-completed ADRe Profile

    Time frame: 4 months from the start of the study

    Comparison of completeness of the ADRe Profile completed through a video call with ADRe Profiles previously completed in person

  2. Inter-rater reliability of patient versus nurse (or nurse-researcher) completed ADRe Profile (Cohen's Kappa).

    Time frame: 4 months from the start of the study

    To determine how much of the potential variability of the records is due to errors in measurement, to estimate a degree to which service users accurately evaluate their symptoms when compared with a nurse researcher. Cohen's Kappa will be calculated.

  3. Calculated percentage and described nature of items on the ADRe Profile that can be populated from accessing the nursing and medical notes.

    Time frame: 16 months from the start of the study

    Establishing the overlap of information - the number and nature of the ADRe items that have previously been collected and recorded in the patients' nursing and medical notes.

  4. Clinical impact on service users, including new problems identified (number and nature) and problems addressed (number and nature)

    Time frame: 16 months from the start of the study

    Number of patients with a change in signs and symptoms related to adverse effects of prescribed medicines. Care quality/ clinical gain/ benefit to patients as recorded in notes and on the Profile by the number and nature of all health problems addressed, particularly serious adverse events.

  5. Prescription changes

    Time frame: 16 months from the start of the study

    Number of patients with changes in prescription regimens: drug or dose. Number and nature of changes.

  6. Description of stakeholder views on ADRe Profile implementation effectiveness (survey rating of the ADRe Profile - Likert scale)

    Time frame: 22 months from the start of the study

    A brief survey will be distributed to the main stakeholders (patients, nurses, GP's and pharmacists) following completion of Randomised Controlled Trial.

  7. Description of stakeholder views on ADRe Profile implementation feasibility (eliciting interview themes)

    Time frame: 22 months from the start of the study

    Semi-structured interview with the main stakeholders (patients, nurses, GP's and pharmacists) to explore their views on feasibility of ADRe Profile integration in GP practices.

Secondary outcomes

  1. Calculation of the average nurses', GP's and pharmacists' length of time per one ADRe Profile completion

    Time frame: 16 months from the start of the study

    Average length of the health professionals' time involvement with one ADRe Profile

  2. Calculation of the cost of nurses', GP's and pharmacists' time, based on average national salary cost per hour.

    Time frame: 16 months from the start of the study

    Estimated costs of ADRe implementation in GP practices

  3. Description of the main stakeholders' views on multidisciplinary collaboration (eliciting interview themes)

    Time frame: 22 months from the start of the study

    Semi-structured interview with the main stakeholders (patients, nurses, GP's and pharmacists) to explore their views on whether and how ADRe Profile contributed to multidisciplinary collaboration between nurses, doctors and pharmacists

  4. Description of the patients' views on the contribution of ADRe Profile to patient-centered care (eliciting interview themes).

    Time frame: 22 months from the start of the study

    Semi-structured interview with the patients to seek their views on whether and how ADRe Profile contributes to patient-centered care

Sponsors and collaborators

Lead sponsor

Swansea University

Other

Collaborators

  • Abertawe Bro Morgannwg University Health Board
  • Hywel Dda Health Board

Registry information

Official study title

Medication Monitoring in General Practice: Clinical Impact of Implementing a Nurse-led Adverse Drug Reaction (ADRe) Profile in Older Adults With 5 or More Prescribed Medicines

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 11, 2020
Registry last updated
Oct 7, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.